Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAX 2

Next Previous
Drug Profile

TAX 2

Alternative Names: AP-01 - Apmonia Therapeutics; AP-02 - Apmonia Therapeutics; TAX-2

Latest Information Update: 19 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CNRS; University of Reims
  • Developer Apmonia Therapeutics
  • Class Antineoplastics; Antithrombotics; Cyclic peptides
  • Mechanism of Action Immunostimulants; Interferon gamma stimulants; Platelet aggregation inhibitors; Thrombospondin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Thrombosis

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Thrombosis

Most Recent Events

  • 02 Mar 2026 Apmonia Therapeutics plans phase I/II in Solid tumours (Late-stage disease, Second-line therapy and greater, Metastatic disease) in France and Belgium (CTIS2025-521164-36-00)
  • 18 Sep 2025 TAX 2 is still in preclinical development in Thrombosis in France (IV, Injection) (Apmonia Therapeutics pipeline, September 2025)
  • 18 Sep 2025 Phase-I/II clinical trials in Solid tumours (Intraperitoneal), before September 2025 (Apmonia Therapeutics pipeline, September 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top